Kymera Announces $150 Million Private Placement Equity Financing
August 19, 2022 07:30 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update
August 09, 2022 07:00 ET
|
Kymera Therapeutics, Inc.
Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413)...
Kymera Therapeutics to Report Second Quarter 2022 Results on August 9
July 27, 2022 07:30 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan
July 08, 2022 07:30 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma
June 01, 2022 08:42 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis
June 01, 2022 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting
May 20, 2022 07:30 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation
May 05, 2022 08:00 ET
|
Kymera Therapeutics, Inc.
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting -Results highlight potential for IRAK4 degraders to broadly impact TLR/IL-1R-driven inflammatory and autoimmune...
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
May 03, 2022 07:00 ET
|
Kymera Therapeutics, Inc.
IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring Clinical...
Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
April 19, 2022 08:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...